Trade Names:Adenocard- Injection 3 mg/mL
Trade Names:Adenoscan- Injection 3 mg/mL
Slows conduction through atrioventricular (AV) node; can interrupt reentry pathways through AV node and restore normal sinus rhythm.
Rapidly cleared from circulation via cellular uptake, primarily by erythrocytes and vascular endothelial cells.
Rapidly metabolized intracellularly to adenosine monophosphate or inosine. Inosine is ultimately degraded to uric acid.
Extracellular adenosine has a t ½ of less than 10 sec in whole blood.
Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with Wolff-Parkinson-White syndrome.
Noninvasive assessment of patients with suspected coronary artery disease in conjunction with thallium tomography. Used with BCNU for treatment of brain tumors.
Second- or third-degree AV block or sick sinus syndrome (except in patients with functioning artificial pacemaker); atrial flutter; atrial fibrillation; ventricular tachycardia.
IV 6 mg as rapid IV bolus (over 1 to 2 sec).Repeat administration (adults)
If first dose does not eliminate PSVT within 1 to 2 min, give 12 mg as rapid IV bolus; 12 mg dose may be repeated a second time if necessary. Doses over 12 mg are not recommended.
Store at room temperature. Do not refrigerate because crystallization may occur. If crystallization has occurred, dissolve crystals by warming to room temperature.
Antagonize effects of adenosine; larger doses of adenosine may be needed.Carbamazepine
May produce higher degrees of heart block.Dipyridamole
Potentiates effects of adenosine; smaller doses may be adequate.
None well documented.
Facial flushing; headache; chest pain; hypotension.
Lightheadedness, dizziness, tingling in arms; numbness.
Dyspnea; shortness of breath; chest pressure.
Monitor BP and cardiac rhythm during and after administration.Transient asystole
Monitor for transient asystole, which may develop during administration.
Category C .
At time of conversion to normal sinus rhythm, new arrhythmias may appear on ECG; these are usually self-limiting.
Adenosine may cause bronchoconstriction.
Drug may produce short-lasting heart block. Patients in whom high-level heart block (eg, third-degree) develops after one dose should not receive repeat doses.
Copyright © 2009 Wolters Kluwer Health.